Plasma and tumor tissue samples from immune checkpoint inhibitor (pembrolizumab and nivolumab)-treated NSCLC patients revealed elevated levels of Wnt and SHH in plasma as well as increased GLI2 levels, suggesting HH and Wnt activation was correlated with immune therapy resistance [80,131]. The gene discussed is GLI2; the disease is neoplasm.